Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Updating mid-term sales guidance: Expect to grow +5% CAGR 2023-2028 and maintaining core margin of ~40%+ by 2027 Company overview Financial review Conclusions Updated mid-term guidance 2023-2028 +5% (cc) expected sales CAGR (previous guidance 2022-27) Illustrative net sales, cc Appendix References 2023 Core margin 36% Mainly EntrestoⓇ PromactaⓇ TasignaⓇ Sandostatin LAR® Gx impact¹ up to 2028 +5% CAGR CC Mainly Fabhalta® ScemblixⓇ (1L) remibrutinib Mainly Kisqali® PluvictoⓇ Leqvio® atrasentan pelacarsen KesimptaⓇ ScemblixⓇ CosentyxⓇ In-market growth drivers²/base business Pipeline probabilized Core margin -40%+ by 2027 2028 Note: All figures reflecting Continuing Operations. 1. For forecasting purposes, we assume Entresto US LoE in 2025. 2. Including indication expansion. Leqvio - licensed from Alnylam Pharmaceuticals, Inc. Pelacarsen - licensed from lonis Pharmaceuticals, Inc. □ NOVARTIS Reimagining Medicine Novartis Q4 Results | January 31, 2024 22

View entire presentation